Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients

Journal of Medical Virology

Volumn 84, Issue 12, 2012, Pages 2018-2025

  van Besouw, Nicole M ^a   Verjans, Georges M G M ^a   Zuijderwijk, Joke M ^a   Litjens, Nicolle H R ^a   Osterhaus, Albert D M E ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Age; Effector cells; IFN ; Memory cells; Transplantation

Indexed keywords

CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON;

ADULT; AGE; AGED; ARTICLE; BLOOD; CELL ASSAY; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HERPES ZOSTER; HUMAN; HUMAN CELL; KIDNEY GRAFT; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; PHENOTYPE; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, CCR7; VIRUS ACTIVATION;

EID: 84867731974     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23427     Document Type: Article

References (36)

1. Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. 2008. Varicella zoster virus-associated disease in adult kidney transplant recipients: Incidence and risk-factor analysis. Transpl Infect Dis 10:260-268.
2. Arnou R, Fiquet A, Thomas S, Sadorge C. 2011. Immunogenicity and safety of ZOSTAVAX((R)) approaching expiry potency in individuals aged ≥50 years. Hum Vaccin 7:1060-1065.
3. Arvin AM. 2001. Varicella-zoster virus. In: Knipe DM, Howley PM, Griffin DE, editors. Fields virolgy. 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins, pp 2731-2760.
4. Arvin AM. 2008. Humoral and cellular immunity to varicella-zoster virus: An overview. J Infect Dis 197:S58-S60.
5. Arvin AM, Sharp M, Moir M, Kinchington PR, Sadeghi-Zadeh M, Ruyechan WT, Hay J. 2002. Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10 29, and 62 of varicella-zoster virus. Viral Immunol 15:507-516.
6. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. 2000. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 181:859-866.
7. De Castro N, Carmagnat M, Kerneis S, Scieux C, Rabian C, Molina JM. 2011. Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults. AIDS Res Hum Retroviruses 27:1089-1097.
8. de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, Boot H. 2006. The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination. Vaccine 24:3946-3952.
9. Distler E, Schnurer E, Wagner E, von Auer C, Plachter B, Wehler D, Huber C, Kolbe K, Meyer RG, Herr W. 2008. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Biol Blood Marrow Transplant 14:1417-1424.
10. Geel A, Zuidema W, van Gelder T, van Doornum G, Weimar W. 2005. Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc 37:952-953.
11. Geginat J, Lanzavecchia A, Sallusto F. 2003. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101:4260-4266.
12. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. 2000. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 342:635-645.
13. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. 2004. Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 4:108-115.
14. Halloran PF, Melk A, Barth C. 1999. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 10:167-181.
15. Hambleton S. 2005. Chickenpox. Curr Opin Infect Dis 18:235-240.
16. Hwang EA, Kang MJ, Han SY, Park SB, Kim HC. 2004. Viral infection following kidney transplantation: Long-term follow-up in a single center. Transplant Proc 36:2118-2119.
17. Jones L, Black AP, Malavige GN, Ogg GS. 2006. Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. J Virol 80:9772-9778.
18. Klein NP, Holmes TH, Sharp MA, Heineman TC, Schleiss MR, Bernstein DI, Kemble G, Arvin AM, Dekker CL. 2006. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine 24:5913-5918.
19. Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G, Hauber J, Steinkasserer A. 2000. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol 74:7127-7136.
20. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. 2003. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188:1336-1344.
21. Marin M, Meissner HC, Seward JF. 2008. Varicella prevention in the United States: A review of successes and challenges. Pediatrics 122:e744-e751.
22. Milikan JC, Baarsma GS, Kuijpers RW, Osterhaus AD, Verjans GM. 2009. Human ocular-derived virus-specific CD4+ T cells control varicella zoster virus replication in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 50:743-751.
23. Morrow G, Slobedman B, Cunningham AL, Abendroth A. 2003. Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 77:4950-4959.
24. Naraqi S, Jonasson O, Jackson GG, Yamashiroya HM. 1978. Clinical manifestations of infections with herpesviruses after kidney transplantation: A prospective study of various syndromes. Ann Surg 188:234-239.
25. Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragon MV, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E. 2007. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866-7872.
26. Otani N, Yamanishi K, Sakaguchi Y, Imai Y, Shima M, Okuno T. 2012. Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster. J Immunol Methods 377:53-55.
27. Patterson-Bartlett J, Levin MJ, Lang N, Schodel FP, Vessey R, Weinberg A. 2007. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 25:7087-7093.
28. Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, Schonrich G. 2001. Targeting the function of mature dendritic cells by human cytomegalovirus: A multilayered viral defense strategy. Immunity 15:997-1009.
29. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. 2008. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: A review. J Infect Dis 197:S224-S227.
30. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712.
31. Soyuncu S, Berk Y, Eken C, Gulen B, Oktay C. 2009. Herpes zoster as a useful clinical marker of underlying cell-mediated immune disorders. Ann Acad Med Singapore 38:136-138.
32. Verkade MA, van Druningen CJ, Op deHoek, CT, Weimar W, Betjes MG. 2007. Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med 7:65-71.
33. Voelker R. 2011. FDA expands age range for shingles vaccine. JAMA 305:1526.
34. Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. 2004. Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 190:72-82.
35. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schodel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ, Investigators USDoVACSPSPS. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200:1068-1077.
36. Weinberg A, Huang S, Song LY, Fenton T, Williams P, Patterson J, Tovar-Salazar A, Levin MJ. 2012. Immune Correlates of Herpes Zoster in HIV-Infected Children and Youth. J Virol 86:2878-2881.